4.6 Article

Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016-2019)

Related references

Note: Only part of the references are listed.
Article Respiratory System

Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia

Roxanne Strachan et al.

Summary: The study found that the 13-valent pneumococcal conjugate vaccine significantly reduced all-cause hospitalisations for bacterial pneumonia, but increased empyema hospitalisations, with pneumococcal ST3 emerging as the dominant serotype in empyema.

THORAX (2021)

Article Microbiology

Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Plan-The Continued Importance of Serotype 3

Catarina Silva-Costa et al.

Summary: The study evaluated the consequences of higher vaccine uptake of PCV13 after its introduction in the National Immunization Plan, finding that even with a vaccine uptake over 95%, PCV13 serotypes remain important causes of pIPD.

MICROORGANISMS (2021)

Article Pediatrics

Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016

Tolulope A. Adebanjo et al.

PEDIATRICS (2020)

Article Medicine, General & Internal

Pediatric parapneumonic effusion before and after national pneumococcal vaccination programs in Taiwan

Jun Yi Sim et al.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2020)

Review Infectious Diseases

Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology

M. A. Fletcher et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)

Article Infectious Diseases

Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR

L. Selva et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)